VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).
Company profile
Ticker
VECT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
SEC CIK
VECT stock data
News
Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2022
1 Jul 22
Piper Sandler Initiates Coverage On VectivBio Holding with Overweight Rating, Announces Price Target of $23
1 Jul 22
71 Biggest Movers From Yesterday
16 Jun 22
55 Stocks Moving In Wednesday's Mid-Day Session
15 Jun 22
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
15 Jun 22
Press releases
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
11 Aug 22
VectivBio Announces Closing of $54 Million Aggregate Financing
29 Jun 22
VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
14 Jun 22
VectivBio Announces Launch of Public Offering of Ordinary Shares
14 Jun 22
VectivBio Publishes Invitation to the Annual General Meeting
9 Jun 22
Analyst ratings and price targets
Calendar
7 Apr 22
12 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
Institutional ownership, Q1 2022
| 13F holders | Current |
|---|---|
| Total holders | 19 |
| Opened positions | 12 |
| Closed positions | 0 |
| Increased positions | 3 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 109.87M |
| Total shares | 28.94M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Orbimed Advisors | 5.33M | $25.11M |
| Novo Holdings A/S | 3.38M | $15.92M |
| CHI Advisors | 3.08M | $14.53M |
| Bpifrance Participations | 2.81M | $0 |
| Bpifrance | 2.81M | $13.22M |
| Versant Venture Capital V | 2.79M | $0 |
| Citadel Advisors | 2.72M | $12.8M |
| Eventide Asset Managment | 2.34M | $10.99M |
| Cormorant Asset Management | 2.08M | $9.79M |
| Tekla Capital Management | 756.5K | $3.56M |
Financial report summary
?Competition
Takeda PharmaceuticalContent analysis
?| Positive | |
| Negative | |
| Uncertain | |
| Constraining | |
| Legalese | |
| Litigous | |
| Readability |
H.S. sophomore Avg
|
Financial reports
Current reports
6-K
Current report (foreign)
1 Jul 22
6-K
VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
16 Jun 22
6-K
Invitation to the 2022 Annual General Meeting
9 Jun 22
6-K/A
VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
7 Apr 22
6-K
VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
7 Apr 22
6-K
VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts
30 Mar 22
6-K
Current report (foreign)
29 Oct 21
6-K
VectivBio Announces Results of Extraordinary General Meeting
3 Sep 21
6-K
VectivBio to Acquire Comet Therapeutics and Host R&D Day
31 Aug 21
6-K
Invitation to the Extraordinary General Meeting
12 Aug 21
Registration and prospectus
424B5
Prospectus supplement for primary offering
16 Jun 22
424B5
Prospectus supplement for primary offering
14 Jun 22
F-3
Shelf registration (foreign)
13 Jun 22
F-3
Shelf registration (foreign)
4 May 22
S-8
Registration of securities for employees
26 Apr 21
424B4
Prospectus supplement with pricing info
9 Apr 21
F-1/A
Registration statement (foreign) (amended)
7 Apr 21
8-A12B
Registration of securities on exchange
6 Apr 21
F-1/A
Registration statement (foreign) (amended)
5 Apr 21
F-1
Registration statement (foreign)
19 Mar 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
13 May 22
CORRESP
Correspondence with SEC
5 May 22
UPLOAD
Letter from SEC
5 May 22
EFFECT
Notice of effectiveness
9 Apr 21
CERT
Certification of approval for exchange listing
8 Apr 21
CORRESP
Correspondence with SEC
5 Apr 21
CORRESP
Correspondence with SEC
5 Apr 21
UPLOAD
Letter from SEC
4 Apr 21
UPLOAD
Letter from SEC
30 Mar 21
CORRESP
Correspondence with SEC
29 Mar 21
Ownership
SC 13D
VectivBio Holding / Forbion Growth Opportunities Fund II Cooperatief U.A. ownership change
7 Jul 22
SC 13D/A
VectivBio Holding / Bpifrance Participations ownership change
28 Jun 22
SC 13G
VectivBio Holding / Cormorant Asset Management ownership change
17 Jun 22
SC 13G
VectivBio Holding / EVENTIDE ASSET MANAGEMENT ownership change
14 Feb 22
SC 13G/A
VectivBio Holding / CITADEL ADVISORS ownership change
14 Feb 22
SC 13G
VectivBio Holding / CHI Advisors ownership change
11 Feb 22
SC 13G
VectivBio Holding / ORBIMED ADVISORS ownership change
10 Feb 22
SC 13G
VectivBio Holding / CITADEL ADVISORS ownership change
23 Apr 21
SC 13D
VectivBio Holding / Bpifrance Participations ownership change
23 Apr 21
SC 13G
VectivBio Holding / ORBIMED ADVISORS ownership change
20 Apr 21
Patents
Utility
Compositions and Methods for the Treatment of Graft Versus Host Disease
28 Jul 22
This application is directed to methods of treating Graft versus Host Disease (GvHD), specifically acute GvHD and acute gastrointestinal GvHD, using apraglutide.
Utility
Manufacture, Formulation and Dosing of Apraglutide
3 Mar 22
The present disclosure relates to methods of making, formulating and administering GLP-2 analogs.
Utility
Manufacture, Formulation and Dosing of Apraglutide
6 Jan 22
The present disclosure relates to methods of making, formulating and administering GLP-2 analogs.